Fulgent: Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 133.33% and 1.90%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Read full article »
Chairman & CEO
Ming Hsieh
Fulgent focuses on developing and commercializing novel formulations of anti-cancer therapeutics.
Read more